Effectiveness of the BNT162b2 vaccine against severe SARS-CoV-2 and COVID-19 infection in children aged 5 to 11 years in Italy: a retrospective analysis from January to April 2022 The Lancet
Effectiveness of the BNT162b2 vaccine against Omicron in children aged 5 to 11 years NEJM nejm.org
The pediatric COVID vaccine is only 51% effective at Omicron, according to the Ynetnews study
Vaccination against COVID-19 for children aged 5 to 11 The Lancet
Efficacy of Pfizer-BioNTech BNT162b2 vaccine against Delta and Omicron SARS-CoV-2 variants among adolescents News-Medical.Net